Zoetis Inc. (NYSE:ZTS) Receives $217.11 Consensus PT from Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have received an average rating of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $217.11.

Several analysts recently issued reports on ZTS shares. BTIG Research boosted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus restated a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th.

Zoetis Trading Up 0.2 %

Shares of ZTS stock opened at $191.17 on Wednesday. The company’s 50-day moving average price is $182.85 and its 200-day moving average price is $174.50. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market cap of $87.23 billion, a price-to-earnings ratio of 36.83, a PEG ratio of 2.91 and a beta of 0.88. Zoetis has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.41 EPS. As a group, equities analysts predict that Zoetis will post 5.84 earnings per share for the current year.

Hedge Funds Weigh In On Zoetis

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. SS&H Financial Advisors Inc. grew its position in shares of Zoetis by 15.4% during the second quarter. SS&H Financial Advisors Inc. now owns 6,118 shares of the company’s stock worth $1,061,000 after buying an additional 818 shares in the last quarter. Heritage Wealth Management Inc. acquired a new position in shares of Zoetis during the second quarter worth about $624,000. Sanctuary Advisors LLC acquired a new position in shares of Zoetis during the second quarter worth about $19,525,000. Clear Rock Advisors LLC grew its position in shares of Zoetis by 8.7% during the second quarter. Clear Rock Advisors LLC now owns 16,427 shares of the company’s stock worth $2,848,000 after buying an additional 1,314 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after purchasing an additional 166,517 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.